Fast Market Research

Report Published: "ImmunoCellular Therapeutics, Ltd. - Product Pipeline Review - 2013"

New Pharmaceuticals research report from Global Markets Direct is now available from Fast Market Research

 
Repost This

Boston, MA -- (SBWIRE) -- 02/06/2014 -- Global Market Direct's pharmaceuticals report, "ImmunoCellular Therapeutics, Ltd. - Product Pipeline Review - 2013" provides data on the ImmunoCellular Therapeutics, Ltd.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct's proprietary databases, ImmunoCellular Therapeutics, Ltd.'s corporate website, SEC filings, investor presentations and featured press releases, both from ImmunoCellular Therapeutics, Ltd. and industry-specific third party sources, put together by Global Markets Direct's team.

View Full Report Details and Table of Contents

Scope

- ImmunoCellular Therapeutics, Ltd. - Brief ImmunoCellular Therapeutics, Ltd. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of ImmunoCellular Therapeutics, Ltd. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of ImmunoCellular Therapeutics, Ltd. with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the ImmunoCellular Therapeutics, Ltd.'s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to Get This Report

- Evaluate ImmunoCellular Therapeutics, Ltd.'s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of ImmunoCellular Therapeutics, Ltd. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the ImmunoCellular Therapeutics, Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with ImmunoCellular Therapeutics, Ltd..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of ImmunoCellular Therapeutics, Ltd. and identify potential opportunities in those areas.

Companies Mentioned in this Report: ImmunoCellular Therapeutics, Ltd.

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- ImmunoCellular Therapeutics, Ltd. (IMUC) - Financial and Strategic SWOT Analysis Review
- Nektar Therapeutics - Product Pipeline Review - 2013
- Addex Therapeutics - Product Pipeline Review - 2013
- Cell Therapeutics, Inc. - Product Pipeline Review - 2013
- Amicus Therapeutics, Inc. - Product Pipeline Review - 2013
- United Therapeutics Corporation - Product Pipeline Review - 2013
- Stemline Therapeutics, Inc. - Product Pipeline Review - 2013
- Acorda Therapeutics, Inc. - Product Pipeline Review - 2013
- e-Therapeutics plc - Product Pipeline Review - 2013
- TG Therapeutics, Inc. - Product Pipeline Review - 2013